Wake-up haul: an Ozempic moment for the brain
Summary
This episode explores the pharmaceutical potential of orexin agonists, which may rival GLP-1 drugs in treating sleep disorders and beyond. It then examines Japan’s weak startup ecosystem, citing capital shortages and cultural stigma as barriers to creating unicorns. Finally, the show discusses the severe financial and health costs of procrastination, offering evidence-based strategies like exercise and mental contrasting to overcome it.
Topics discussed
Orexin agonists: The next big thing in pharma?
Japan's lost startup charm: From Sony to stagnation
Capital shortage: Why Japan lacks venture funding
Cultural stigma against entrepreneurship in Japan
The problem of rushing to IPO in Japan
Government reforms and the rise of AI unicorns
The high costs of procrastination on health and income
Why we procrastinate more than previous generations
Mental contrasting: A technique to beat procrastination
How physical exercise reduces procrastination
Diet, ADHD meds, and future treatments for procrastination
Listen ad-free on Castria